Status:
UNKNOWN
Fluorescence, Light-microscopy, Ultrasound Integrated / Intraoperative Diagnosis to MAXimise Resection
Lead Sponsor:
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Conditions:
Patients With Radiological, Clinical and Anamnestic Picture Compatible With a New Diagnosis of Glioblastoma
Eligibility:
All Genders
18-90 years
Brief Summary
The present study aims to evaluate and compare with the histopathological analysis the various margin-assessment systems, including ultrasound, florescence, brightfield vision, new optical filters and...
Detailed Description
Extent of Resection represents the cornerstone of surgery in terms of improving the prognosis of the patient with High Grade Gliomas, but total removal of neoplastic tissue is prevented by the amount ...
Eligibility Criteria
Inclusion
- Patients with radiological, clinical and anamnestic picture compatible with a new diagnosis of Glioblastoma for whom there is an indication for cytoreductive surgery at the Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta.
Exclusion
- Patients aged less than 18 years at the time of radiological diagnosis
- Patients who have received radiation therapy in the same area as the neoplasm of interest
- Patients contraindicated to 5-ALA administration
- Patients whose neoplasm is in close proximity to functionally eloquent areas (Primary Motor, Broca's, Wernicke's areas)
- Patients who have not given their consent to take part in the research
Key Trial Info
Start Date :
April 8 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 8 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05330559
Start Date
April 8 2022
End Date
April 8 2024
Last Update
April 15 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.